在细胞实验中,
SP600125(JNK Inhibitor II,AbMole,M2076)的使用浓度范围较广。例如,在人神经母细胞瘤SH-SY5Y细胞中,30 μM 的SP600125可显著抑制JNK磷酸化并保护细胞免受异氟烷诱导的损伤[1];在MG-63和Saos-2骨肉瘤细胞中,5 μM的SP600125被用于细胞癌变机制研究[2];SP600125(NSC75890)在大鼠心肌细胞H9c2中,以剂量依赖方式抑制高尿酸(HUA)诱导的脂肪积累及脂ogenic基因表达[3];SP600125在MC3T3-E1成骨前体细胞中,可逆转镉诱导的Runx2下调并提升细胞存活率[4];10 μM SP600125在人胶质母细胞瘤细胞(GBMCs)中,处理24小时后显著抑制增殖并上调HIF-1α与BMP4表达[5];SP600125在MH7A类风湿关节炎滑膜成纤维细胞中,还能有效抑制MMP-3表达,提示JNK/MMP通路可能是关节炎研究的新靶点[6];SP600125(1PMV)在肺上皮细胞中,能阻断AREG 诱导的c-Jun磷酸化及上皮-间质转化(EMT)过程[7];在HPDLSCs(牙周膜干细胞)中,SP600125可逆转Wnt5a 对成骨分化的抑制作用[8];
SP600125(JNK Inhibitor II,AbMole,M2076)在BMSCs(骨髓间充质干细胞)中,减轻TNF-α 诱导的p53、caspase-9/-3上调,改善细胞迁移能力[9]。
SP600125(JNK Inhibitor II,AbMole,M2076)在动物实验中,常通过腹腔注射(i.p.)给药,少部分为脑室注射(i.c.v.)给药,剂量多为10–50 mg/kg。例如,在RAG-2−/−小鼠A673肉瘤模型中,50 mg/kg剂量显著抑制肿瘤生长并降低VEGF表达与微血管密度(MVD),同时提高凋亡指数[10];在大鼠局灶性脑缺血再灌注(MCAO)模型中,i.c.v.给予SP600125可减轻脑梗死体积并改善行为异常[11];SP600125在心肌缺血再灌注损伤大鼠模型中,与Ulinastatin(乌司他丁)联用可降低p-JNK表达并减少心肌细胞凋亡[12]。
范例详解
Mol Med. 2025 May 15;31(1):190.
科研人员在上述文章中使用了
SP600125(JNK Inhibitor II,AbMole,M2076)。实验人员探究了脂质运载蛋白-2(LCN2)介导铁死亡机制在光诱导光感受器退化中的作用,结果显示:光暴露显著诱导LCN2在光感受器细胞和视网膜中的表达,LCN2通过增加细胞内Fe²⁺水平和激活JNK通路,抑制SLC7A11-GSH-GPX4轴,从而诱导铁死亡。SP600125是一种选择性JNK抑制剂,通过阻断JNK通路激活,证实了上述发现。
图 1. LCN2 regulated ferroptosis in 661 W photoreceptor cells by modulating the JNK pathway[13].
参考文献及鸣谢
[1] Yang, Z.; Lv, J.; Lu, X.; et al. Emulsified isoflurane induces release of cytochrome C in human neuroblastoma SHSY-5Y cells via JNK (c-Jun N-terminal kinases) signaling pathway.
Neurotoxicology and teratology 2018,
65, 19-25.
[2] Wang, L.; Wang, J.; Chu, X.; et al. Cholesterol and steroid synthesis pathways may be involved in the inhibition of osteosarcoma cell viability by calcium-sensing receptor antagonism.
PeerJ 2026,
14, e20546.
[3] Xie, D.; Zhao, H.; Lu, J.; et al. High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling.
American journal of physiology. Endocrinology and metabolism 2021,
320 (6), E1032-e1043.
[4] Ou, L.; Wang, H.; Wu, Z.; et al. Effects of cadmium on osteoblast cell line: Exportin 1 accumulation, p-JNK activation, DNA damage and cell apoptosis.
Ecotoxicology and environmental safety 2021,
208, 111668.
[5] Kose, C.; Uslu, S.; Calik-Kocaturk, D.; et al. JNK Inhibition Modulates the Cytoskeleton, Hypoxia, and Neurogenesis on the Protein Level in Glioblastoma Cells and Astrocytes: An Immunofluorescence Study.
Turkish neurosurgery 2023,
33 (6), 982-989.
[6] Kanai, T.; Kondo, N.; Okada, M.; et al. The JNK pathway represents a novel target in the treatment of rheumatoid arthritis through the suppression of MMP-3.
Journal of orthopaedic surgery and research 2020,
15 (1), 87.
[7] Cheng, W. H.; Kao, S. Y.; Chen, C. L.; et al. Amphiregulin induces CCN2 and fibronectin expression by TGF-β through EGFR-dependent pathway in lung epithelial cells.
Respiratory research 2022,
23 (1), 381.
[8] Hasegawa, D.; Wada, N.; Yoshida, S.; et al. Wnt5a suppresses osteoblastic differentiation of human periodontal ligament stem cell-like cells via Ror2/JNK signaling.
Journal of cellular physiology 2018,
233 (2), 1752-1762.
[9] Wei, B.; Bai, X.; Chen, K.; et al. SP600125 enhances the anti-apoptotic capacity and migration of bone marrow mesenchymal stem cells treated with tumor necrosis factor-alpha.
Biochemical and biophysical research communications 2016,
475 (4), 301-307.
[10] Huang, Y. C.; Pan, W.; Li, H.; et al. c-Jun NH2-terminal kinase suppression significantly inhibits the growth of transplanted breast tumors in mice.
The Journal of international medical research 2020,
48 (6), 300060520929858.
[11] Yamazaki, Y.; Arita, K.; Harada, S.; et al. Activation of c-Jun N-terminal kinase and p38 after cerebral ischemia upregulates cerebral sodium-glucose transporter type 1.
Journal of pharmacological sciences 2018,
138 (4), 240-246.
[12] Yang, Z. H.; Lu, Y. J.; Gu, K. P.; et al. Effect of ulinastatin on myocardial ischemia-reperfusion injury through JNK and P38 MAPK signaling pathways.
European review for medical and pharmacological sciences 2019,
23 (19), 8658-8664.
[13] Tang, W.; Zhai, R.; Ma, J.; et al. Lipocalin-2-mediated ferroptosis as a target for protection against light-induced photoreceptor degeneration.
Molecular medicine (Cambridge, Mass.) 2025,
31 (1), 190.